ICP\u2013MS analysis of glass fragments of Parthian and Sasanian epoch from Seleucia and Veh Ardasir (Central Iraq)

Forty-one glass fragments were analysed by inductively coupled plasma \u2013 mass spectrometry, determining 40 major, minor and trace elements, including rare earth elements. The fragments came from excavations carried out at the archaeological sites of Seleucia and Veh Ardasir in modern Iraq, and were dated to the Parthian and Sasanian epochs. Analytical data indicate that all the samples are silica\u2013soda\u2013lime glasses. Magnesium and potassium oxide contents below 1% suggest that eight out of nine glasses from Seleucia, dating from between the first and the third century AD, could have been obtained by use of an evaporite as a flux; the same conclusion can be drawn for some of the Sasanian glasses dating from the fourth and fifth centuries AD. The other glasses from Veh Ardasir, as well as the remaining sample from Seleucia, are characterized by higher contents of magnesium and potassium, which suggests recourse to plant ash; different magnesium and phosphorus contents allow one to separate these samples into two main groups, pointing to the use of different kinds of plant ash. Aluminium and calcium contents, together with trace element data, may indicate that different sands were used for preparing glasses of different composition. Samples from Seleucia and Veh Ardasir are mainly blue\u2013green and green to yellow\u2013green, respectively; iron and manganese contents suggest that the furnace atmosphere was mainly responsible for the development of these hues

Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies

OBJECTIVE: To assess the antihypertensive efficacy of olmesartan medoxomil and ramipril on 24-h ambulatory blood pressure (ABP) in elderly hypertensive patients by pooled data analysis of two studies with identical designs (one Italian, one European). METHODS: After a 2-week placebo wash-out 1453 elderly hypertensive patients (65-89 years; sitting office DBP 90-109 mmHg and/or sitting office SBP 140-179 mmHg) were randomized to a 12-week double-blind treatment with olmesartan medoxomil 10 mg or ramipril 2.5 mg once-daily, up-titrated (20 and 40 mg olmesartan medoxomil; 5 and 10 mg ramipril) after 2 and 6 weeks in patients without normalized office BP. 24-h ABP was recorded at randomization and after 12 weeks. RESULTS: In 715 patients with valid baseline and end-of-treatment recordings baseline-adjusted 24-h SBP and DBP reductions were greater with olmesartan medoxomil (n = 356) than with ramipril (n = 359) [between-treatment differences and 95% confidence interval (CI), SBP: 2.2 (3.8, 0.6), P = 0.006; DBP: 1.3 (2.2, 0.3), P = 0.009]. Olmesartan medoxomil showed larger BP reductions in the last 6 h from the dosing interval and higher smoothness indices than ramipril. Olmesartan medoxomil reduced the SBP morning rise [-2.8 (-4.9, -0.8) mmHg], whereas ramipril did not [+1.5 (-0.6, +3.6) mmHg; P = 0.004 between-treatments]. Five hundred and eighty-two patients with sustained hypertension (office and 24-h ambulatory hypertension) showed the largest antihypertensive effect, with between-treatment differences still in favor of olmesartan medoxomil [SBP: 2.1 (3.9, 0.4), P = 0.019; DBP: 1.2 (2.3, 0.1), P = 0.032]. CONCLUSIONS: Olmesartan medoxomil provides a more effective and sustained 24-h BP control than ramipril in elderly hypertensive patients, particularly in the hours farthest from last intak